Keyphrases
Stem Cells
100%
Ovarian Cancer
100%
Cancer Targeting
100%
MEK Inhibitor (MEKi)
100%
High-grade Serous Ovarian Cancer (HGSOC)
100%
Src Inhibition
100%
Tumor-initiating
100%
Cancer Growth
100%
Kinase Inhibition
60%
Saracatinib
60%
Proteomic Analysis
40%
Xenograft
40%
Dual Therapy
40%
Selumetinib
40%
Sphere Formation
40%
Tumor-initiating Cells
40%
Aldehyde Dehydrogenase 2 (ALDH2)
40%
Clinical Trials
20%
Tumor
20%
Therapeutic Potential
20%
Autophagy
20%
Apoptosis Induction
20%
Human Epidermal Growth Factor Receptor 2 (HER2)
20%
Life Cycle Analysis
20%
Cancer Genome Atlas
20%
Targeted Therapy
20%
Cell Cycle Arrest
20%
Overall Survival
20%
Tumor Inhibition
20%
ErbB2
20%
Kinase Activation
20%
Apoptotic Genes
20%
Gene Expression Analysis
20%
Combination Treatment
20%
Multivariate Analysis
20%
Cancer Population
20%
Synergistic Induction
20%
Src Activation
20%
In Vitro Inhibition
20%
Src Inhibitor
20%
Xenografting
20%
Primary Ovarian Cancer
20%
Gene Analysis
20%
Apoptosis Analysis
20%
Cell Cycle Inhibition
20%
Signaling Kinases
20%
Cancer Stem Cells
20%
Medicine and Dentistry
Neoplasm
100%
Ovarian Cancer
100%
Cancer Growth
100%
Mitogen-Activated Protein Kinase
44%
Phosphotransferase
44%
Cancer Stem Cell
33%
Saracatinib
33%
Xenograft
22%
Selumetinib
22%
Cell Cycle
22%
Proteomics
22%
Targeted Therapy
11%
In Vitro
11%
Clinical Trial
11%
Programmed Cell Death
11%
Gene Expression
11%
Autophagy
11%
Kinase
11%
Overall Survival
11%
Epidermal Growth Factor Receptor
11%
The Cancer Genome Atlas
11%
MEK Inhibitor
11%
Kinase Signaling
11%
Cancer Inhibition
11%
Cancer Cell Culture
11%
Src Inhibitor
11%
Apoptosis
11%
Multivariate Analysis
11%
Cell Cycle Arrest
11%
Biochemistry, Genetics and Molecular Biology
Kinase
100%
Phosphotransferase
100%
Mitogen-Activated Protein Kinase
100%
Cancer Stem Cell
75%
Proteomics
50%
Cell Cycle
50%
Gene Expression
25%
Clinical Trial
25%
Epidermal Growth Factor Receptor
25%
Autophagy
25%
Cell Cycle Arrest
25%
Multivariate Analysis
25%
MEK Inhibitor
25%
Cancer Cell Culture
25%
Overall Survival
25%
Pharmacology, Toxicology and Pharmaceutical Science
Neoplasm
100%
Ovary Cancer
100%
Cancer Growth
100%
Phosphotransferase
44%
Saracatinib
33%
Malignant Neoplasm
22%
Selumetinib
22%
Clinical Trial
11%
Cancer Inhibition
11%
Epidermal Growth Factor Receptor
11%
Mitogen Activated Protein Kinase Kinase Inhibitor
11%
Overall Survival
11%
Apoptosis
11%